Mr. Lenz joined ADMA as Vice President, Chief Financial Officer in May 2012 and was instrumental in preparing the Company to go public and begin trading on the NASDAQ in October 2013. In June 2018, Mr. Lenz was promoted to Executive Vice President and Chief Financial Officer. Mr. Lenz co-led the Biotest Therapy Business Unit (“BTBU”) acquisition team. In this role, Mr. Lenz was responsible for integrating all financial reporting and financial operations, as well as ensuring the seamless integration of all human resources activities and information technology systems during and after the transaction.
Mr. Lenz’s financial and operational leadership experience includes completing numerous capital markets equity financings, negotiating multiple significant credit facilities, leading strategic transactions, licensing and collaboration arrangements throughout his 25-year career, serving both public and private companies in the life sciences and medical device sectors. He leads ADMA’s investor relations efforts and continues to oversee the Company’s financial reporting and SOX compliance activities amongst other operational duties.
Prior to joining ADMA, Mr. Lenz was at CorMedix Inc., a developmental-stage pharmaceutical and medical device company, where he held the position of Chief Financial Officer from February 2010 to May 2012 and Chief Operating Officer and Chief Financial Officer from January 2012 to May 2012. Prior to joining CorMedix, Mr. Lenz served as Chief Financial Officer of Arno Therapeutics, Inc. from July 2008 to February 2010, Chief Financial Officer of VioQuest Pharmaceuticals, Inc. from April 2004 to June 2008, Controller of Chiral Quest, Inc., a subsidiary of VioQuest Pharmaceuticals, from October 2003 to March 2004, Controller of Smiths Detection from July 2000 to October 2003, and senior auditor at KPMG LLP from October 1998 to July 2000.
Mr. Lenz received a B.S. from Rider University, an M.B.A. from Saint Joseph’s University and is a licensed Certified Public Accountant in New Jersey.
Mr. Lenz is the finance committee co-chairperson for BioNJ. He has actively been involved in advising biotechs, pharmaceutical companies, venture capitalists, debt lenders and hedge funds.
Mr. Lenz has received multiple awards for his various accomplishments as CFO, which include: Best Growth Manager, Financier of the Year, Public Company and Capital Success.
What is Brian Lenz's net worth?
The estimated net worth of Brian Lenz is at least $13.61 million as of August 15th, 2023. Mr. Lenz owns 782,013 shares of ADMA Biologics stock worth more than $13,607,026 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Lenz may own. Learn More about Brian Lenz's net worth.
How do I contact Brian Lenz?
Has Brian Lenz been buying or selling shares of ADMA Biologics?
Brian Lenz has not been actively trading shares of ADMA Biologics during the last quarter. Most recently, Brian Lenz sold 211,578 shares of the business's stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $4.60, for a transaction totalling $973,258.80. Following the completion of the sale, the chief financial officer now directly owns 782,013 shares of the company's stock, valued at $3,597,259.80. Learn More on Brian Lenz's trading history.
Who are ADMA Biologics' active insiders?
Are insiders buying or selling shares of ADMA Biologics?
During the last year, insiders at the biotechnology company sold shares 10 times. They sold a total of 1,221,795 shares worth more than $13,540,539.83. The most recent insider tranaction occured on November, 22nd when CFO Brad L Tade sold 15,000 shares worth more than $317,250.00. Insiders at ADMA Biologics own 3.7% of the company.
Learn More about insider trades at ADMA Biologics. Information on this page was last updated on 11/22/2024.
